면역측정법 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 기술별, 용도별, 검체별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Immunoassay Market Size, Share & Trends Analysis Report By Product, By Technology, By Application, By Specimen, By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

면역측정법 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 면역측정법 시장 규모는 2025-2030년에 걸쳐 CAGR 4.59%를 나타내며, 2030년에는 351억 달러에 달할 것으로 예측됩니다.

PoC 신속 검사와 자동 면역측정법 분석 장치의 도입이 시장 성장을 뒷받침하고 있으며, 만성 질환과 감염증 증가가 높은 시장 성장으로 이어지고 있습니다.

미국 암 협회에 따르면 2020년 암 환자/생존자 수는 추정 1,690만명이었습니다. 2019년 암으로 인해 약 60만 6,880명이 사망했습니다. 이처럼 암으로 진단되는 증례 수 증가가 면역측정법 수요를 촉진하고 있습니다.

또한 감염과 예방 대책에 대한 의식이 높아져 신속 진단 검사 제품에 대한 높은 수요로 이어져 매출을 늘리고 있습니다. 2018의 조사에 따르면 제조체는 2017년에 라터럴 플로우 어세이의 매출을 2억 7,600만으로 보고했으며, 2017년 사하라 이남의 아프리카에서 약 75.0%의 말라리아 사례가 라터럴 플로우 어세이를 이용하여 진단되었다고 보고되었습니다.

일부 스마트폰 기반 장비와 관련 툴이 차세대 POC(Point of Care) 진단 및 검사 장비로 등장하여 시장의 성장을 뒷받침하고 있습니다. 예를 들어, 심근경색에서 심장 트로포닌 I의 신속한 검사를 위해 자율 모세혈관 미세 유체 칩과 결합된 스마트폰 애플리케이션이 사용됩니다. 이 플랫폼은 자원이 제한된 환경에서도 쉽게 사용할 수 있으며, 12분 이내에 검사 결과를 얻을 수 있습니다.

미국에서 Aptio 자동화된 Atellica 면역측정법 솔루션의 첫 번째 도입은 2018년 4월에 Siemens 의료 GmbH에 의해 발표되었습니다. Coulter는 COVID-19 항원 검출을 위한 최초의 고품질뿐만 아니라 처리량 분석을 발표했으며 공식 이름은 Access SARS-CoV-2 Antigen assay가 되었습니다. 2018년 7월, 시그너스 테크놀로지스와 자이로 프로테인 테크놀로지스는 바이오 치료용 독소를 식별하기 위한 면역 분석법을 개발하기 위해 협력했습니다. 양사의 전략적 제휴는 주로 바이오 분석 솔루션의 제공과 바이오 치료 제조의 효율화에 중점을 둡니다.

면역측정법 시장 보고서 하이라이트

• 2024년에는 맞춤형 의료와 질병에 대한 표적 요법 수요 증가에 견인되어 키트 및 시약이 66.10%의 점유율로 시장을 견인했습니다.
• 면역측정법 산업에 있어서의 감염증 용도의 점유율은 66.10%로 시장을 리드하고, 예측 기간 중의 CAGR은 5.43%를 나타낼 것으로 예측됩니다.
• 효소 면역측정법은 맞춤형 의료, 암 진단, 심혈관 질환 검사, 감염증 검출을 중심으로 2024년에는 63.90% 시장 점유율을 확보했습니다.
• 혈액은 2024년에 41.54%의 최대 시장 점유율을 차지해 면역측정법의 실시에 사용되는 최대의 시료였습니다.
• 2024년, 면역측정법 산업에 있어서의 병원의 점유율은 32.54%, 기타는 예측 기간 중에 CAGR 5.45%를 나타낼 것으로 예측됩니다.
• 북미의 면역측정법 시장은 2024년에 47.43%로 최대의 매출 점유율을 차지했지만, 이는 주로 견고한 의료 시스템, 만성 질환의 높은 발생률, 새로운 진단 기술에 대한 의식의 높아짐에 지지되고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 면역측정법 시장 변수, 동향, 범위

• 시장 소개/계통 전망
• 시장 규모와 성장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 면역측정법 시장 분석 툴
  • Porter's Five Forces 분석
  • PESTEL 분석

제4장 면역측정법 시장 : 제품별, 추정·동향 분석

• 면역측정법 시장 : 제품 변동 분석
• 제품별(2024년, 2030년)
• 분석, 키트, 시약
  • ELISA 시약 및 키트
  • 신속 검사 시약 및 키트
  • ELISPOT 시약 및 키트
  • Western Blot 시약 및 키트
  • 기타 시약 및 키트
• 분석기/기기
  • 개방형 시스템
  • 폐쇄형 시스템
• 소프트웨어 및 서비스

제5장 면역측정법 시장 : 용도별, 추정·동향 분석

• 면역측정법 시장 : 용도 변동 분석
• 용도별(2024년, 2030년)
• 치료 약물 모니터링
• 종양학
• 심장학
• 내분비학
• 전염병 검사
• 자가면역질환
• 기타

제6장 면역측정법 시장 : 기술별, 추정·동향 분석

• 면역측정법 시장 : 기술 변동 분석
• 기술별(2024년, 2030년)
• 방사 면역측정법(RIA)
• 효소 면역측정법(EIA)
  • 화학발광 면역측정법(CLIA)
  • 형광 면역측정법(FIA)
• 신속검사
• 기타

제7장 면역측정법 시장 : 검체별, 추정·동향 분석

• 면역측정법 시장 : 검체 변동 분석
• 검체별(2024년, 2030년)
• 혈액
• 타액
• 소변
• 기타

제8장 면역측정법 시장 : 최종 용도별, 추정·동향 분석

• 면역측정법 시장 : 최종 용도 변동 분석
• 최종 용도별(2024년, 2030년)
• 병원
• 혈액 은행
• 임상 실험실
• 제약 및 생명 공학 기업
• 학술연구센터
• 기타

제9장 면역측정법 시장 : 지역별, 추정·동향 분석

• 면역측정법 시장 점유율, 지역별(2024년, 2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업 분류
• 기업 히트맵 분석
• 기업 프로파일
• Abbott
• Siemens Healthineers AG
• Danaher Corporation(Beckman Coulter)
• bioMerieux SA
• Quidel Corporation
• Sysmex Corporation
• Ortho Clinical Diagnostics
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG
• Becton, Dickinson, and Company
• Thermo Fisher Scientific, Inc.

KTH

영문 목차

영문목차

Immunoassay Market Growth & Trends:

The global immunoassay market size is expected to reach USD 35.10 billion by 2030, registering a CAGR of 4.59% from 2025 to 2030, according to a new report by Grand View Research, Inc. The introduction of PoC rapid tests and automated immunoassay analyzers is boosting market growth. In addition, the rising number of chronic and infectious diseases is leading to high market growth.

According to the American Cancer Society, there were an estimated 16.9 million cancer patients/survivors in 2020. Around 1.8 million cancer cases were diagnosed in the U.S., according to the National Cancer Institute 2019 data. According to the American Cancer Society, nearly 606,880 deaths occurred due to cancer in the U.S. in 2019. Thus, the rise in the number of cancer cases being diagnosed is driving the demand for immunoassays. This is expected to boost the market growth in the coming years.

Furthermore, growing awareness regarding infectious diseases and preventive measures has led to a high demand for rapid diagnostic test products, thereby increasing sales. Based on a survey by the WHO on the World malaria report 2018, manufacturers reported sales of 276 million for lateral flow assays in 2017. It also reported that around 75.0% of malaria cases were diagnosed using lateral flow assays in sub-Saharan Africa in 2017.

Several smartphone-based devices and associated tools have emerged as next-generation point-of-care diagnostics or testing devices, thereby boosting the market growth. For instance, a smartphone application combined with the autonomous capillary microfluidic chip is used for the rapid testing of cardiac troponin I in myocardial infarction. This platform can be easily used in resource-limited settings, providing test results within 12 minutes. Thus, novel technological advancements are anticipated to further drive the market over the forecast period.

The first implementation of the Atellica immunoassay solutions with Aptio automation in the United States was announced by Siemens Healthcare GmbH in April 2018. The objective of this product was designed to promote advanced technological products in the U.S. In December 2020, Beckman Coulter, a Danaher business, introduced its first high-quality as well as throughput assay for the COVID-19 antigen detection, officially named Access SARS-CoV-2 Antigen assay. In July 2018, Cygnus Technologies and Gyros Protein Technologies collaborated to produce immunoassay to identify biotherapeutic toxins. The two companies' strategic alliance will primarily focus on offering bioanalytical solutions and increasing biotherapeutics manufacturing efficiencies.

Immunoassay Market Report Highlights:

• In 2024, kits and reagents led the market with a 66.10% share, driven by increasing demand for personalized medicine and targeted therapies for diseases. However, the software and services of the immunoassays segment is projected to grow at the fastest CAGR during the forecast period and are delivering testing services for clinical and research uses.
• The infectious disease application in the immunoassay industry led the market with a 66.10% share and is expected to grow at a CAGR of 5.43% over the forecast period. Oncology and autoimmune diseases are projected to grow at a significant growth during the forecast period.
• Enzyme immunoassays secured the dominant market share in 2024 of 63.90% focusing on personalized medicine, cancer diagnostics, cardiovascular disease testing, and infectious disease detection. However, the others segment is projected to grow at the fastest CAGR during the forecast period.
• Blood held the largest market share of 41.54% in 2024, being the largest specimen used for performing immunoassays. Urine is expected to be the fastest-growing segment over the forecast period, driven by its non-invasive nature, ease of collection, and widespread application in disease diagnostics.
• In 2024, the hospitals in the immunoassay industry held a 32.54% share. Others are projected to grow at a CAGR of 5.45% during the forecast period.
• North America immunoassay market held the largest revenue share at 47.43% in 2024, primarily supported by robust healthcare systems, a high incidence of chronic illnesses, and a growing awareness of new diagnostic technologies. Asia Pacific is set to record the fastest CAGR, propelled by healthcare reforms, infrastructure enhancements, and a large patient pool.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Immunoassay Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Rising incidence of chronic and infectious diseases
    • 3.3.1.2. Increasing demand for point-of-care diagnostics
    • 3.3.1.3. Growing demand for portable and automated immunoassays
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Lower detection limit
    • 3.3.2.2. Limitations associated with immunoassay techniques
• 3.4. Immunoassay Market Analysis Tools
  • 3.4.1. Porter's Five Forces Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Immunoassay Market: Product Estimates & Trend Analysis

• 4.1. Immunoassay Market: Product Movement Analysis
• 4.2. Immunoassay Market Estimates and Forecasts, by Product 2024 & 2030 (USD Million)
• 4.3. Assays, Kits, and Reagents
  • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. ELISA Reagents & Kits
    • 4.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.3. Rapid Tests Reagents & Kits
    • 4.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.4. ELISPOT Reagents & Kits
    • 4.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.5. Western Blot Reagents & Kits
    • 4.3.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.6. Other Reagents & Kits
    • 4.3.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Analyzers/Instruments
  • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Open Ended Systems
    • 4.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Closed Ended Systems
    • 4.4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Software and Services
  • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Immunoassay Market: Application Estimates & Trend Analysis

• 5.1. Immunoassay Market: Application Movement Analysis
• 5.2. Immunoassay Market Estimates and Forecasts, by Application 2024 & 2030 (USD Million)
• 5.3. Therapeutic Drug Monitoring
  • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Oncology
  • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Cardiology
  • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Endocrinology
  • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Infectious Disease Testing
  • 5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Autoimmune Diseases
  • 5.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Immunoassay Market: Technology Estimates & Trend Analysis

• 6.1. Immunoassay Market: Technology Movement Analysis
• 6.2. Immunoassay Market Estimates and Forecasts, by Technology 2024 & 2030 (USD Million)
• 6.3. Radioimmunoassay (RIA)
  • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Enzyme Immunoassays (EIA)
  • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Chemiluminescence Immunoassays (CLIA)
    • 6.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Fluorescence Immunoassays (FIA)
    • 6.4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Rapid Test
  • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Immunoassay Market: Specimen Estimates & Trend Analysis

• 7.1. Immunoassay Market: Specimen Movement Analysis
• 7.2. Immunoassay Market Estimates and Forecasts, by Specimen 2024 & 2030 (USD Million)
• 7.3. Blood
  • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Saliva
  • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Urine
  • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Immunoassay Market: End Use Estimates & Trend Analysis

• 8.1. Immunoassay Market: End--use Movement Analysis
• 8.2. Immunoassay Market Estimates and Forecasts, by End-use 2024 & 2030 (USD Million)
• 8.3. Hospitals
  • 8.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Blood Banks
  • 8.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Clinical Laboratories
  • 8.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Pharmaceutical and Biotech Companies
  • 8.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Academic Research Centers
  • 8.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. Others
  • 8.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Immunoassay Market: Regional Estimates & Trend Analysis

• 9.1. Immunoassay Market Share, By Region, 2024 & 2030 (USD Million)
• 9.2. North America
  • 9.2.1. North America Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key Country Dynamics
    • 9.2.2.2. Target Disease Prevalence
    • 9.2.2.3. Competitive Scenario
    • 9.2.2.4. Regulatory Framework
    • 9.2.2.5. Reimbursement Scenario
    • 9.2.2.6. U.S. Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2.3. Canada
    • 9.2.3.1. Key Country Dynamics
    • 9.2.3.2. Target Disease Prevalence
    • 9.2.3.3. Competitive Scenario
    • 9.2.3.4. Regulatory Framework
    • 9.2.3.5. Reimbursement Scenario
    • 9.2.3.6. Canada Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2.4. Mexico
    • 9.2.4.1. Key Country Dynamics
    • 9.2.4.2. Target Disease Prevalence
    • 9.2.4.3. Competitive Scenario
    • 9.2.4.4. Regulatory Framework
    • 9.2.4.5. Reimbursement Scenario
    • 9.2.4.6. Mexico Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.3. Europe
  • 9.3.1. Europe Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Target Disease Prevalence
    • 9.3.2.3. Competitive Scenario
    • 9.3.2.4. Regulatory Framework
    • 9.3.2.5. Reimbursement Scenario
    • 9.3.2.6. UK Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.3. Germany
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Target Disease Prevalence
    • 9.3.3.3. Competitive Scenario
    • 9.3.3.4. Regulatory Framework
    • 9.3.3.5. Reimbursement Scenario
    • 9.3.3.6. Germany Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.4. France
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Target Disease Prevalence
    • 9.3.4.3. Competitive Scenario
    • 9.3.4.4. Regulatory Framework
    • 9.3.4.5. Reimbursement Scenario
    • 9.3.4.6. France Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.5. Italy
    • 9.3.5.1. Key Country Dynamics
    • 9.3.5.2. Target Disease Prevalence
    • 9.3.5.3. Competitive Scenario
    • 9.3.5.4. Regulatory Framework
    • 9.3.5.5. Reimbursement Scenario
    • 9.3.5.6. Italy Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.6. Spain
    • 9.3.6.1. Key Country Dynamics
    • 9.3.6.2. Target Disease Prevalence
    • 9.3.6.3. Competitive Scenario
    • 9.3.6.4. Regulatory Framework
    • 9.3.6.5. Reimbursement Scenario
    • 9.3.6.6. Spain Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.7. Denmark
    • 9.3.7.1. Key Country Dynamics
    • 9.3.7.2. Target Disease Prevalence
    • 9.3.7.3. Competitive Scenario
    • 9.3.7.4. Regulatory Framework
    • 9.3.7.5. Reimbursement Scenario
    • 9.3.7.6. Denmark Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.8. Sweden
    • 9.3.8.1. Key Country Dynamics
    • 9.3.8.2. Target Disease Prevalence
    • 9.3.8.3. Competitive Scenario
    • 9.3.8.4. Regulatory Framework
    • 9.3.8.5. Reimbursement Scenario
    • 9.3.8.6. Sweden Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.9. Norway
    • 9.3.9.1. Key Country Dynamics
    • 9.3.9.2. Target Disease Prevalence
    • 9.3.9.3. Competitive Scenario
    • 9.3.9.4. Regulatory Framework
    • 9.3.9.5. Reimbursement Scenario
    • 9.3.9.6. Norway Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Competitive Scenario
    • 9.4.2.4. Regulatory Framework
    • 9.4.2.5. Reimbursement Scenario
    • 9.4.2.6. Japan Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.3. China
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Competitive Scenario
    • 9.4.3.4. Regulatory Framework
    • 9.4.3.5. Reimbursement Scenario
    • 9.4.3.6. China Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.4. India
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Competitive Scenario
    • 9.4.4.4. Regulatory Framework
    • 9.4.4.5. Reimbursement Scenario
    • 9.4.4.6. India Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.5. Australia
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Target Disease Prevalence
    • 9.4.5.3. Competitive Scenario
    • 9.4.5.4. Regulatory Framework
    • 9.4.5.5. Reimbursement Scenario
    • 9.4.5.6. Australia Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.6. South Korea
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Target Disease Prevalence
    • 9.4.6.3. Competitive Scenario
    • 9.4.6.4. Regulatory Framework
    • 9.4.6.5. Reimbursement Scenario
    • 9.4.6.6. South Korea Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.7. Thailand
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Target Disease Prevalence
    • 9.4.7.3. Competitive Scenario
    • 9.4.7.4. Regulatory Framework
    • 9.4.7.5. Reimbursement Scenario
    • 9.4.7.6. Thailand Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.5. Latin America
  • 9.5.1. Latin America Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Competitive Scenario
    • 9.5.2.4. Regulatory Framework
    • 9.5.2.5. Reimbursement Scenario
    • 9.5.2.6. Brazil Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.3. Argentina
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Competitive Scenario
    • 9.5.3.4. Regulatory Framework
    • 9.5.3.5. Reimbursement Scenario
    • 9.5.3.6. Argentina Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.6. Middle East and Africa
  • 9.6.1. Middle East and Africa Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Competitive Scenario
    • 9.6.2.4. Regulatory Framework
    • 9.6.2.5. Reimbursement Scenario
    • 9.6.2.6. South Africa Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Competitive Scenario
    • 9.6.3.4. Regulatory Framework
    • 9.6.3.5. Reimbursement Scenario
    • 9.6.3.6. Saudi Arabia Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.4. UAE
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Target Disease Prevalence
    • 9.6.4.3. Competitive Scenario
    • 9.6.4.4. Regulatory Framework
    • 9.6.4.5. Reimbursement Scenario
    • 9.6.4.6. UAE Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Target Disease Prevalence
    • 9.6.5.3. Competitive Scenario
    • 9.6.5.4. Regulatory Framework
    • 9.6.5.5. Reimbursement Scenario
    • 9.6.5.6. Kuwait Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis by Key Market Participants
• 10.2. Company Categorization
• 10.3. Company Heat Map Analysis
• 10.4. Company Profiles
• 10.5. Abbott
  • 10.5.1. Participant's Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Benchmarking
  • 10.5.4. Recent Developments/ Strategic Initiatives
• 10.6. Siemens Healthineers AG
  • 10.6.1. Participant's Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Benchmarking
  • 10.6.4. Recent Developments/ Strategic Initiatives
• 10.7. Danaher Corporation (Beckman Coulter)
  • 10.7.1. Participant's Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Benchmarking
  • 10.7.4. Recent Developments/ Strategic Initiatives
• 10.8. bioMerieux SA
  • 10.8.1. Participant's Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Benchmarking
  • 10.8.4. Recent Developments/ Strategic Initiatives
• 10.9. Quidel Corporation
  • 10.9.1. Participant's Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Benchmarking
  • 10.9.4. Recent Developments/ Strategic Initiatives
• 10.10. Sysmex Corporation
  • 10.10.1. Participant's Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Benchmarking
  • 10.10.4. Recent Developments/ Strategic Initiatives
• 10.11. Ortho Clinical Diagnostics
  • 10.11.1. Participant's Overview
  • 10.11.2. Financial Performance
  • 10.11.3. Product Benchmarking
  • 10.11.4. Recent Developments/ Strategic Initiatives
• 10.12. Bio-Rad Laboratories, Inc.
  • 10.12.1. Participant's Overview
  • 10.12.2. Financial Performance
  • 10.12.3. Product Benchmarking
  • 10.12.4. Recent Developments/ Strategic Initiatives
• 10.13. F. Hoffmann-La Roche AG
  • 10.13.1. Participant's Overview
  • 10.13.2. Financial Performance
  • 10.13.3. Product Benchmarking
  • 10.13.4. Recent Developments/ Strategic Initiatives
• 10.14. Becton, Dickinson, and Company
  • 10.14.1. Participant's Overview
  • 10.14.2. Financial Performance
  • 10.14.3. Product Benchmarking
  • 10.14.4. Recent Developments/ Strategic Initiatives
• 10.15. Thermo Fisher Scientific, Inc.
  • 10.15.1. Participant's Overview
  • 10.15.2. Financial Performance
  • 10.15.3. Product Benchmarking
  • 10.15.4. Recent Developments/ Strategic Initiatives

관련자료